Israele - ebraico - Ministry of Health

takeda israel ltd - dexlansoprazole - קפסולות בשחרור מושהה - dexlansoprazole 30 mg - dexlansoprazole

Israele - ebraico - Ministry of Health

takeda israel ltd - dexlansoprazole - קפסולות בשחרור מושהה - dexlansoprazole 30 mg - dexlansoprazole

Israele - ebraico - Ministry of Health

takeda israel ltd - dexlansoprazole - קפסולות בשחרור מושהה - dexlansoprazole 60 mg - dexlansoprazole

Israele - ebraico - Ministry of Health

takeda israel ltd - dexlansoprazole - קפסולות בשחרור מושהה - dexlansoprazole 60 mg - dexlansoprazole

Israele - ebraico - Ministry of Health

abbvie biopharmaceuticals ltd, israel - adalimumab 40 mg / 0.8 ml - solution for injection - pen - adalimumab - * rheumatoid arthritis: humira in combination with methotrexate is indicated for: - the treatment of moderate to severe active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. humira has been shown to reduce the rate of progression of joint damage as measured by x-ray adn to impove physical function when given in combination with methotrexate. * crohn's disease : humira is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohn's disease who have had an inadequate response to conventional therapy.humira is indicated for reducing signs and symptoms and inducing clinical r

Israele - ebraico - Ministry of Health

abbvie biopharmaceuticals ltd, israel - adalimumab 40 mg / 0.8 ml - solution for injection - pfs - adalimumab - * rheumatoid arthritis: humira in combination with methotrexate is indicated for: - the treatment of moderate to severe active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. humira has been shown to reduce the rate of progression of joint damage as measured by x-ray adn to impove physical function when given in combination with methotrexate. * crohn's disease : humira is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohn's disease who have had an inadequate response to conventional therapy.humira is indicated for reducing signs and symptoms and inducing clinical r

Israele - ebraico - Ministry of Health

abbvie biopharmaceuticals ltd, israel - adalimumab 40 mg / 0.8 ml - solution for injection - vial - adalimumab - * rheumatoid arthritis: humira in combination with methotrexate is indicated for: - the treatment of moderate to severe active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. humira has been shown to reduce the rate of progression of joint damage as measured by x-ray adn to impove physical function when given in combination with methotrexate. * crohn's disease : humira is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohn's disease who have had an inadequate response to conventional therapy.humira is indicated for reducing signs and symptoms and inducing clinical r

Israele - ebraico - Ministry of Health

j-c health care ltd - infliximab - אבקה להכנת תרכיז לאינפוזיה - infliximab 100.0 mg/vial - infliximab - infliximab - - adult :crohn's disease: treatment of severe active crohn's disease in patients who have not responded despite of a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant. treatment of fistulising crohn's disease in patients who have not responded despite of a full and adequate course of therapy with conventional treatment. -paediatric crohn's disease: remicade is indicated for: treatment of severe active crohn's disease in paediatric patients aged 6 to 17 years who have not responded to conventional therapy including a corticosteroid an immunomodulator and primary nutrition therapy or who are intolerant to or have contraindications for such therapies. remicade has been studied only in combination with conventional immunosuppressive therapy -ankylosing spondylitis: remicade is indicated for: treatment of ankylosing spondylitis in patients who have severe axial symptoms elevated serological markers of inflammatory activity and who have responded inadequately to conventional ther

Israele - ebraico - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - infliximab - אבקה להכנת תמיסה מרוכזת לעירוי - infliximab 100 mg - infliximab

Israele - ebraico - Ministry of Health

padagis israel agencies ltd, israel - infliximab - אבקה להכנת תמיסה מרוכזת לעירוי - infliximab 100 mg/vial - infliximab